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1. Introduction 
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death 
worldwide resulting in between 250,000 to one million deaths per annum. It carries dismal 
prognosis and the number death is close to the incidence of disease owing to the aggressive 
nature of this tumor. The incidence of HCC is highest in China, eastern Asia, and Saharan 
African. The main etiology of HCC in these regions is chronic hepatitis B viral infection. In 
most Western countries, HCC is mainly related to hepatitis C infection and alcoholic liver 
disease. Nonalcoholic steato-hepatitis and exposure to aflatoxins are also known risk factors 
for development of HCC.  
Advanced non-resectable HCC has a median survival of only 6 months [1]. Traditional 
cytotoxic chemotherapy has not been found to be effective in prolonging overall survival 
and is associated with significant hematological toxicities. The use of systemic 
chemotherapy is also limited by liver cirrhosis which often coexists in these patients. 
2. Molecular biology and mechanism of HCC 
Pathogenesis of HCC is a complex process. HCC is believed to be related to genetic 
alterations caused by chronic liver injury and inflammation. Cytokines release induced by 
death of hepatocytes, fibrogenesis, and liver cirrhosis are the early events marking 
hepatocarcinogenesis. Occasionally, however, HCC can arise in liver without evidence of 
chronic cirrhosis. Chronic infections with hepatitis B or C viruses are 2 important etiologies 
in development of this tumor. Integration of viral DNA in the human genome can 
potentially induce chromosomal instability, activate oncogenes or deactivate tumor-
suppressor genes, promoting cancer formation. Known examples of mutations in the tumor 
suppressor genes or proto-oncogenes in HCC include p53, p73, APC, Rb, c-myc and cycline 
D1 [2]. Various viral proteins, such as HBs or preS in hepatitis B and core protein in HCV, 
have been linked to activation of transcription and cellular proliferation, although the exact 
mechanism is not known.  
Cytogenic studies have shown chromosomal amplification or deletions are common in 
HCC. HCC is associated with high prevalent amplifications in 1q, 6p, 9q, 11q (contains areas 
encoding cyclin D1), 17q, and 20q [2, 3], and high prevalent deletions in 4q, 6p (contains 
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areas encoding VEGFA), 8p, 13q, 16q, and 17p [3]. Increase in tolemerase activity leading to 
telomere shortening and genomic instability, was also observed in nearly 90% of HCC [4]. 
The significance of these chromosomal alteration remains to be elucidated.  
The advance of microarray in the last 2 decades have revolutionized oncological studies and 
shed light on the molecular mechanisms behind development of cancer. In many tumors, 
molecular studies successfully identified specific genes that drive the growth of 
malignancies, leading to development of targeted therapies for each tumor subtypes. For 
instance, imatinib was designed to block the tyrosine kinase activity associated with the 
kinase fusion protein BCR-ABL in chronic myeloid leukemia and became the standard of 
care for this tumor. Gefitinib and erlotinib targeting the tyrosine kinase activation caused by 
mutated EGFR in adenocarcinoma of lung, and significantly prolonged the life expectancy 
of patients carrying this genetic abnormality. However such pattern of oncogene addiction 
has not been identified in HCC. Today, a large body of knowledge have been accumulated 
to stratify specific gene expressions involved in various stages of HCC tumorgenesis [5]. For 
instance, early HCC development is marked by down-regulation of Toll-like receptor 
pathway, Jak/STAT pathway, TGF pathway, and the insulin-signaling pathway, with up-
regulation of Wnt signaling pathway. Poorly differentiated HCC is characterized by 
decreased level of apoptosis-related proteins compared with well differentiated counterpart 
[6]. Furthermore, many scientists have demonstrated that HCC can be divided into 
prognostic significant subgroups based on gene signatures [7-11]. Although there is yet 
consensus on genetic classification of HCC, these data suggested HCC is a group of 
heterogeneous tumors each with distinct characteristics. This knowledge can path the future 
development of personalized medicine in treatment of HCC.  
While our knowledge on genetic features of HCC continue to expand, much research focus 
on factors that govern more universal processes such as tumor cells proliferation, 
neovascularization, tumor invasion, and metastasis. Today, growth of HCC is considered as 
a result of dysregulation of pleiotropic growth factor signaling [12]. Implicated pathways 
include insulin-like growth factor/IGF-1 receptor (IGF/IGF-1R), hepatocyte growth factor 
(HGF/c-MET), stem cell growth factor receptor (c-kit), Wingless (Wnt/┚-catenin/FZD), 
transforming growth factor ┚ (TGF┚/T┚R), epidermal growth factor/EGF receptor 
(EGF/EGFR), and many growth factor regulated angiogenic signaling such as fibroblast 
growth factor/FGF receptor (FGF/FGFR), platelet growth factor/PDGF receptor 
(PDGF/PDGFR), and vascular endothelial growth factor/VEGF receptor (VEGF/VEGFR). 
Activation by ligand binding on the extracellular portion of these transmembrane receptors 
results in phosphorylation of cytoplastic components, triggering downstream signaling 
cascades. These pathways are multifunctional and crosstalk to each other. The 
RAF/MEK/ERK pathway and phosphatidylinositol-3 kinase (P13K)/AKT/mammalian 
target of rapamycin (mTOR) pathway are some of the major intracellular cascades 
implicated in HCC.  
3. Anti-angiogenic therapy 
HCC is a characterized by its high vascularity and anti-angiogenesis becomes an intense 
area of study in the quest of new therapy for HCC. Angiogenesis plays a pivotal role in the 
growth to solid tumor. It is a complex multi-step process mediated by various 
proangiogenic growth factors such as BEFG, FGFs, TGF┚, interleukin-8 (IL8), 
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metalloproteinase-2 (MMP-2), angiopoietin (Ang), and PDGF. Genetic changes in tumor 
cells and hypoxia induced by rapid tumor growth could lead to increased secretion of these 
mediators, which promote migration, proliferation and survival of endothelial cells, as well 
as growth of stromal cells and extracellular matrix favoring these processes.  
3.1 Sorafenib 
Sorafenib (Bayer 43-9006; Nexavar) is a multikinase inhibitor of the VEGR-2, VEGFR-3, and 
PDGF receptor ┚, and blocks cellular proliferation mediated by the Raf/MAPK/ERK 
signaling pathway [13]. Two Phase III randomized placebo-controlled trails, the SHARP 
trial and the Asian-Pacific trial, have shown overall survival benefit using single agent 
sorafenib as first line treatment in advanced HCC [14, 15]. The SHARP trial contains mainly 
Westerners, whose etiology factors were predominantly HCV infection and alcoholic liver 
cirrhosis. It demonstrated sorafenib led to an improvement of median time to progression 
(TTP) from 2.8 to 5.5 months and overall survival (OS) from 7.9 to 10.7 months, when 
compared with the placebo group. The Asian-Pacific trial, where most subjects were 
Orientals, also found sorafenib improved median TTP from 1.4 to 2.8 months and OS from 
4.2 to 6.5 months when compared with the placebo group. Based on these 2 independent 
studies, sorafenib become the first systemic treatment approved by the U.S. Food and Drug 
Administration (FDA) and many regulatory authorities worldwide for first line 
management of advanced HCC. It should be noted that, however, the absolute benefit of 
sorafenib in HCC remains modest. In both studies the OS improvement was between 2.3 to 
2.8 months. The overall response rate was 24% in the Western study and 57% in the Asia-
Pacific study, but most patients had stable disease and only 3% had partial response. 
Furthermore, over 95% of subjects in these 2 studies had Child-Pugh class A liver function, 
rendering the effect in those with poorer liver function controversial. Child-Pugh  B or C 
liver cirrhosis commonly coexist in patients with HCC. A number of small retrospective 
series showed patients with Child-Pugh B liver function were more likely to have 
hyperbilirubinemia, encephalopathy, worsening of ascites, and shorter survival when given 
sorafenib [16-18]. Since patients with poor liver function would naturally have more of these 
complications and shorter survival, the safety and survival benefit of sorafenib in these 
patients is not known. A recently published abstract of the GIDEON study probably 
provides more insight on this issue. It is so far the largest prospective non-interventional 
study of sorafenib involving over 3000 patients with unresectable HCC. Patients were 
stratified according to different Child-Pugh status, with the safety and outcome of sorafenib 
treatment evaluated [19]. Interim analysis showed Child-Pugh B patients, compared with 
Child-Pugh A patients, did not have a higher incidence of drug-related adverse events 
(AEs), but had a higher incidence of liver-associated AEs. Kaplan Meier estimate showed 
similar TTP between 2 groups, and an obviously worse OS in patients with Child-Pugh B or 
C liver cirrhosis. Most deaths were due to HCC or underlying liver disorders and the 
differences in patient outcomes across Child-Pugh groups appeared to be attributed by 
differences in prognosis.  
Combination therapy has been a common approach in cancer treatment. By acting on 
multiple sites of the cell proliferation pathways, there are potential for enhanced efficacy by 
synergistic effect, reducing the emergence of resistance clones, or minimizing the 
accumulated toxicities of high dose therapy.  
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In an attempt to enhance the effect of sorafenib, many clinical trials are undergoing to 
evaluate the addition of other biological agents to this drug. For example, SEARCH is a 
Phase III randomized placebo controlled, double blind trial of sorafenib plus erlotinib versus 
sorafenib plus placebo as first line systemic treatment for hepatocellular carcinoma.  
Sorafenib has been combined with a number of chemotherapy. Abou-Alfa’s team has 
published a double-blinded randomized phase II trial comparing doxorubicin with or 
without sorafenib. Doxorubicin was extensively studied in treatment of advanced HCC in 
the pre-sorafenib era. It showed minimal efficacy with significant toxicities. In this phase II 
study, combination sorafenib and doxorubicin showed some activity but only gave a 4% 
response rate, and the additional effect of chemotherapy was questionable since this study 
used doxorubicin as the control arm [20].  
3.2 Bevacizumab 
HCC is a highly vascularized tumor and it correlates with high level of VEGF expression 
[21], which is thought to be the most important proangiogenic growth factors. Bevacizumab 
is a humanized recombinant monoclonal antibiody against VEGF with high affinity [22] and 
has been shown to have efficacy in many solid tumors. Bevacizumab as a single agent has 
been shown to have activity in advanced HCC. In Siegel’s Phase II study which enrolled 46 
patients with HCC, bevacizumab (5 mg/kg or 10 mg/kg every 2 weeks) had a response rate 
of 13%, gave a PFS of 6.9 months and median OS of 12.4 months [23]. However, the use of 
this drug is complicated by significant hemorrhage in 11% and thrombosis in 6% of subjects. 
Interestingly, when bevacizumab (10 mg/kg every 2 weeks) was combined with 
chemotherapy gencitabine and oxaliplatin, the combination achieved an apparently higher 
RR of 20%, but yielded a median PFS and medial OS of only 5.3 months and 9.6 months 
respectively with major complications being leucopenia, transaminitis, hypertension and 
fatigue [24]. As chemotherapy appears to have limited role in the development of systemic 
treatment of HCC, the M.D. Anderson group brought forward the concept of combining 
bevacizumab with another biological agent. In their Phase II trial using bevacizumab with 
erlotinib which involved 57 patients [25], the combination gave a median PFS of 7.9 months 
and medial OS of 12.8 months. It is worth noting that 6 patients in this trial terminated 
treatment due to toxicities, but there were an impressive stable disease (SD) rate of 62% and 
partial response (PR) rate of 28%. This study also included both Child-Pugh A and Child-
Pugh B patients although the proportion was not mentioned in the abstract. Meanwhile the 
same research group is exploring the effect of this drug combination compared with 
sorafenib as first line treatment in advanced HCC in a Phase II trial. In summary, early 
clinical trials showed that bevacizumab has some activity in HCC, but efficacy and safety of 
this drug needs to be clarified as it can potentially be associated with major complication 
such as thrombosis, hemorrhage and even death. 
3.3 Sunitinib 
The VEGF family is the most important proangiogenic mechanism known today. VEGF 
binds to cell surface receptors VEGFR-1, 2, and 3 on endothelial cells. Among these 3 
receptors, VEGFR-2 is the primary tyrosine kinase receptor mediating the VEGF signaling. 
Sunitinib is another anti-angiogenic agent with potent anti-VEGF-2 activity. The 
concentration required to produce 50% inhibition (IC50) of human VEGFR-2 kinase activity 
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is 0.009 µM compared with 0.09 µM for sorafenib [13, 26]. It is also an oral multi-targeted 
tyrosine kinase inhibitor with overlapping TKI activities with those of sorafenib, including 
VEGF receptors, RET kinases, PDGFR-┙ and ┚, c-Kit, Flt-3 and colony-stimulating factor 
receptor type 1 [26]. It was first approved for treatment of advanced renal cell carcinoma 
(RCC) [27], which is a highly vascularized tumor also resistant to traditional chemotherapy. 
In RCC, sunitinib and sorafenib demonstrated similar efficacy, thus it was suggested that 
they might also have comparable effect in advanced HCC. The use of single agent sunitinib 
as first line treatment in advanced HCC has been tested in a number of Phase II trials (see 
Table 1 for details) [28-30]. In these trials, sunitinib was given at 37.5 mg daily or 50 mg 
daily for 4 weeks out of a 6-week cycle, or continuously at 37.5 mg daily. The RR was 
relative low, with medial PFS between 2.8-5.3 months, and medial OS between 8 to 9.8 
months. These data showed preliminarily encouraging survival time approximate those of 
sorafenib. Nevertheless, use of sunitnib in HCC requires vigorous testing in randomized 
controlled trial. Cheng et al. released their early Phase III data comparing sunitinib and 
sorafenib as first line treatment in an abstract form recently [31]. In their  open-label trial 
involving over 1000 Child-Pugh A patients with advanced HCC, patients were randomized 
1:1 to receive sunitinib 37.5 mg daily or sorafenib 400 mg BID. The primary end point was 
OS and secondary endpoint was PFS, time to progression (TTP) and safety. The trial was 
terminated prematurely, as interim analysis showed sunitinib had significantly shorter OS 
of 8.1 months compared with 10.0 months of sorafenib (p=0.019). There was no difference in 
PFS and TTP between 2 groups. Serious adverse events (AEs) in sunitnib and sorafenib 
groups were found in 44% and 36% of patients, and grade 5 AEs in 18% and 16% of patients 
respectively. Thus sunitinib failed its primary OS endpoint and was associated with more 
significant toxicities. Worth noting is that in this study, there was no OS difference between 
2 groups among hepatitis B carriers. Formal report of toxicity profile is pending. These 
results did not support using sunitib as first line treatment in advanced HCC and sorafenib 
remains the standard choice. Use of sunitnib as second line treatment after sorafenib failure 
has also been reported by Yau et al. In this Phase II study which enrolled 35 patients, the RR 
was 6%, TTP was 2.9 months and OS was 5.2 months [32]. More clinical data is needed to 
elucidate the role of this TKI in treatment of advanced HCC.  
3.4 Brivanib 
Besides VEGF, the fibroblast growth factor (FGF) pathway is another key driver of 
angiogenesis. FGF is a potent angiogenic growth factor which stimulates induction and 
migration of endothelial cell precursors during vascular development [33]. It is also secreted 
by HCC and contributes to tumor growth [34]. Experiences from other cancers showed the 
expression of  FGF and other angiogenic factors were upregulated upon anti-VEGF 
treatment, suggesting FGF pathway is one of the alternate escape mechanisms that 
contributes to resistance or failure of anti-VEGF treatment [35]. Brivanib (BMS-582664) is a 
novel TKI of both VEGF and Basic FGF (bFGF). In a Phase II open-label study of brivanib as 
first line treatment of unresectable HCC involving 55 patients, brivanib achieved a median 
PFS of 2.7 months and median OS of 10 months. Stable disease, partial response, and 
complete response were found in 22, 3, and 1 patients respectively [36]. Common adverse 
events included fatigue, hypertension and diarrhea. In view of shown activity and 
manageable toxicity profile, brivanib has been carried on to a Phase III multi-center double-
blinded randomized controlled trial (BRISK FL study) which compares this drug with 
sorafenib as first line treatment of HCC. This trial has completed recruitment in July 2011 
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and data collection is underway. The same group of researchers who performed the Phase II 
brivanib trial also tested the efficacy of this drug in patients who failed prior antiangiogenic 
therapy. They recruited 22 such patients; of the 19 patients who were assessed for efficacy, 
58% had stable disease. Alpha fetoprotein reduction of more than half was also found in 
43% of patients [37]. This VEGF / FGF dual targeting agent can potentially become a new 
anti-angiogenic therapy in advanced HCC.  
3.5 Pazopanib 
Pazopanib (GW786034) is multi-targeted TKI of VEGFR1-3, PDGFR-┙ and ┚, and c-kit [38]. 
It shares with sunitinib and sorafenib similar preclinical activity in various xenograft tumors 
models including RCC, thyroid cancer, pancreatic cancer, and HCC [39]. Since it has no 
significant in vitro effect in proliferation of most tumor cell lines, it is believed its anti-tumor 
property owes to its anti-angiogenic activity. Clinically pazopanib has been approved by the 
U.S. FDA for treatment of advanced RCC [40] and has been shown to have promising 
activity in thyroid cancer [41] and urothelial cancer. Its use in HCC is still under preliminary 
research. Our group has recently published a Phase I tudy evaluating the early efficacy and 
pharmacological properties of pazopanib in HCC patients [42]. In this study of 28 patients, 
the maximum tolerated dose was 600 mg daily. The most common adverse events were 
diarrhea, skin hypopigmentation, and AST elevation. Grade 3 dose-limiting toxicities were 
observed in only 2 patients at the 800 mg dose level. Furthermore, 73% of patients 
responded with either partial response or stable disease. These results suggested pazopanib 
has acceptable toxicity and can potentially be a candidate for treatment of advanced HCC.  
3.6 Other anti-angiogenic agents 
Linifanib (ABT-869) is a novel and potent selective inhibitor of the EGF and PDGF families 
of RTKs. In a Phase II open-label trial, 44 Child-Pugh A or B patients with unresectable HCC 
were given linifanib at 0.25 mg/kg daily and 0.25 mg/kg alternate day respectively [43]. The 
overall response rate was 6.8%. For Child-Pugh A patients, median TTP was 5.4 months and 
median OS was 9.7 months. The most common grade 3 or 4 adverse events were 
hypertension and fatigue. A Phase III trial comparing linifanib with sorafenib is undergoing.  
TSU-68 is another multi-targeted TKI with activity against VEGFR, PDGFR, and FGFR. In a 
Phase I/II trial, Kanai et al. reported an overall response rate of 51% with 2.9% complete 
response, 5.7% partial response and 42.8% stable disease. The median TTP was 2.1 months 
and median OS was 13.1 months [44]. Adverse events include diarrhea, malaise, and ALT / 
AST elevation, and were similar to other TKIs. This drug showed preliminary efficacy with 
acceptable safety profile.  
Cediranib (AZD2171) is another investigational TKI activity against pan-VEGFR, PDGFR, c-
kit an FLT-4 pathways. Recently published Phase II data suggested cediranib at 45 mg daily 
bared significant toxicity and did not show clinical response [45].  
Axitinib (AG013736) is a multi-targated TKI with activity against VEGFR1-3, PDGFR and c-
kit. This drug has encouraging survival data as both first and second line treatment in 
advanced RCC, and has shown promising activity in thyroid cancer [46, 47]. Phase II/III 
trials testing this drug in HCC is under planning.  
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The hepatocyte growth factor (HGF) and its receptor called mesenchymal epithelial 
transition factor (c-MET) is another potential target for treatment of HCC. The HGF/c-
MET is involved in growth of hepatocytes [48]. The c-MET mediates cell growth, 
survival, motility and morphogeneis during early development of liver, as well as repair 
and regeneration in liver injury [49]. Foretinib (GSK1363089) is a novel receptor TKI 
targeting c-MET and VEGFR2/KDR in a Phase 1-2 clinical trial for systemic treatment of 
HCC.  
4. Resistance to antiangogenic therapy  
The mechanism underlying resistance to antiangiogenic treatment in HCC is still poorly 
understood. The proposed mechanisms include:  
4.1 Redundancy of angiogenic signaling pathways 
Tumour dependence on pro-angiogenic factors may be altered after the treatment with 
sorafenib [50]. The vascular remodeling that due to pericytic over-coverage renders the 
neovasculature less responsive to VEGF for growth dependence effectively circumventing a 
blocked signaling pathway with greater dependence on other alternate mechanisms [51].  
4.2 Resistance occur at the tumour endothelial cell level 
Published evidence has shown that tumour endothelial cells may harbor unstable genome 
[52]. These aberrant genomes may lead to an increase in genetic alterations and result in 
mutations in the endothelial cells. Thus, the mutated endothelial cells may acquire resistance 
to molecularly targeted therapy.  
4.3 Increase the biological aggressiveness of the tumour following antiangioneic use  
It has been shown that the inhibition of VEGF receptors may result in an increased 
propensity for metastatic dissemination as the hypoxic microenvironment associated with 
the sorafenib use selects for highly aggressive, invasive tumour cells [53, 54]  
4.4 Splitting of pre-existing vasculature 
Antiangiogenic agents inhibit sprouting angiogensis which heavily relies on the need for 
endothelial cell proliferation and migration. Tumour cells can potentially evade these 
pruning effects by the splitting of pre-existing vasculature into new blood vessels without a 
need for VEGF expression and endothelial cell proliferation[55] or form blood vessels 
without the need for endothelial cell proliferation [56]. 
4.5 Increase in the expression of the resistance efflux proteins 
Resistance efflux proteins are members of the ATP binding cassette transporters, especially 
multidrug resistance protein 2(MRP2) may partly account for the development of sorafenib 
resistance. In vitro experiment performed by Shibayama et al. demonstrated that sorafenib is 
a substrate for MRP2 and thus MRP2 may implicate in the development of drug resistance 
to Sorafenib [57].  
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4.6 Presence of cancer stem cell  
Cancer stem cells are typified by a capacity for self-renewal, relative quiescence and the 
ability to differentiate. Evidence has suggested that CSCs are involved in carcinogenesis, 
tumour invasion and metastases, and resistance to various forms of therapies, including 
chemotherapy[58]. 
5. Conclusion 
The development of sorafenib marked an important milestone in the systemic treatment of 
advanced HCC. This drug remains the only approved targeted therapy shown to have 
survival advance in randomized controlled studies. Hepatocarcinogenesis is a complex 
process involving multiple growth factor systems which interact with each other. Early 
clinial trials suggested that agents with single-target activity probably cannot block HCC 
growth and multi-targeted therapies might be the trend for future drug development. As 
HCC in different stages demonstrated different molecular characteristics, and knowledge on 
molecular subgroups of HCC is expanding, we see the vast varieties of potential for 
development of HCC treatment.  
 
Agents Study n 
Response rate 
(%) 
Median PFS 
(months) 
Median 
OS 
(months) 
Sorafenib  
Sorafenib vs. placebo SHARP 602 24.4 5.5 10.7 
Sorafenib vs. placebo 
Asia-
Pacific
226 57.3 5.5 6.5 
Sorafenib + erlotinib
Vs 
Sorafenib + placebo
SEARCH Ongoing 
Bevacizumab  
Bevacizumab Siegel 2008 46 13 6.9 12.4 
Bevacizumab+gemcitabine & 
oxaliplatin 
Zhu 2006 33 
20
(SD 27%)
5.3 9.6 
Bevacizumab+erlotinib Kaseb 57 
(SD 62%,
PR 28%)
7.9 12.8 
Sunitinib  
Sunitinib (37.5mg daily 4/6 
weeks) 
Zhu [28] 34 2.9 3.9 9.8 
Sunitinib (50mg daily 4/6 
weeks) 
Faivre [29] 37 2.7% 5.3 8 
Sunitinib (37.5mg daily 
continuous) 
Koeberle 
[30]
45  2.8 9.3 
Sunitinib vs. sorafenib Cheng 2011 1073 Not a/v 3.6 vs. 2.9 
8.1 vs. 10.0 
(p < 0.01) 
Brivanib  
Brivanib (800 mg daily) Park 2011 55 47% 2.7 10 
Brivanib vs. sorafenib BRISK FL Ongoing
Table 1. First line trials for major antiangiogenic agents (shaded trials indicate Phase III studies) 
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